What is Wedbush's Estimate for Scholar Rock FY2025 Earnings?

Key Points

• Wedbush has lowered its FY2025 earnings per share estimate for Scholar Rock to ($3.00), down from a previous forecast of ($2.98), maintaining an "Outperform" rating with a price target of $50.00.
• Scholar Rock reported a quarterly loss of ($0.98) EPS, missing the consensus estimate of ($0.66), highlighting continued challenges in achieving profitability.
• Scholar Rock is currently rated as "Buy" on average by analysts, with a consensus price target of $46.40, indicating investor optimism despite recent earnings setbacks.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Equities research analysts at Wedbush lowered their FY2025 earnings per share (EPS) estimates for Scholar Rock in a research note issued to investors on Tuesday, September 23rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($3.00) per share for the year, down from their previous forecast of ($2.98). Wedbush currently has a "Outperform" rating and a $50.00 price target on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock's Q4 2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.67) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.59) EPS, FY2027 earnings at ($1.64) EPS and FY2028 earnings at ($0.69) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same period last year, the firm earned ($0.60) earnings per share.

Several other research analysts have also recently weighed in on SRRK. Raymond James Financial set a $53.00 price objective on Scholar Rock and gave the stock a "strong-buy" rating in a research report on Wednesday, July 30th. HC Wainwright cut their price objective on Scholar Rock from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday. Cantor Fitzgerald assumed coverage on Scholar Rock in a research report on Thursday, July 17th. They issued an "overweight" rating on the stock. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Finally, Leerink Partners assumed coverage on Scholar Rock in a research report on Monday, September 15th. They issued an "outperform" rating and a $51.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. Based on data from MarketBeat.com, Scholar Rock presently has an average rating of "Buy" and an average price target of $46.40.

Scholar Rock Stock Down 0.1%

SRRK stock opened at $33.72 on Thursday. The stock's fifty day simple moving average is $34.33 and its two-hundred day simple moving average is $33.06. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.21. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The stock has a market cap of $3.24 billion, a P/E ratio of -11.59 and a beta of 0.36.

Insider Buying and Selling at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $32.53, for a total transaction of $32,725.18. Following the sale, the director directly owned 33,914 shares in the company, valued at approximately $1,103,222.42. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey S. Flier sold 11,136 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total value of $445,662.72. Following the sale, the director owned 24,070 shares in the company, valued at approximately $963,281.40. The trade was a 31.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,739 shares of company stock worth $1,516,584 over the last ninety days. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently made changes to their positions in SRRK. Wellington Management Group LLP raised its stake in shares of Scholar Rock by 763.8% during the 4th quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company's stock valued at $74,581,000 after purchasing an additional 1,525,845 shares during the period. Vestal Point Capital LP purchased a new position in Scholar Rock during the first quarter worth about $41,795,000. Norges Bank purchased a new position in Scholar Rock during the second quarter worth about $41,628,000. RA Capital Management L.P. grew its position in Scholar Rock by 6,351.3% during the first quarter. RA Capital Management L.P. now owns 1,136,453 shares of the company's stock worth $36,537,000 after buying an additional 1,118,837 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Scholar Rock during the second quarter worth about $33,062,000. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.